JP2023528017A5 - - Google Patents

Info

Publication number
JP2023528017A5
JP2023528017A5 JP2022573138A JP2022573138A JP2023528017A5 JP 2023528017 A5 JP2023528017 A5 JP 2023528017A5 JP 2022573138 A JP2022573138 A JP 2022573138A JP 2022573138 A JP2022573138 A JP 2022573138A JP 2023528017 A5 JP2023528017 A5 JP 2023528017A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022573138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528017A (ja
JP7858550B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/064098 external-priority patent/WO2021239838A2/en
Publication of JP2023528017A publication Critical patent/JP2023528017A/ja
Publication of JP2023528017A5 publication Critical patent/JP2023528017A5/ja
Priority to JP2025279763A priority Critical patent/JP2026062799A/ja
Application granted granted Critical
Publication of JP7858550B2 publication Critical patent/JP7858550B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022573138A 2020-05-26 2021-05-26 重症急性呼吸器症候群コロナウイルス2(sars-cov-2)ポリペプチドおよびワクチン目的でのその使用 Active JP7858550B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025279763A JP2026062799A (ja) 2020-05-26 2025-12-24 重症急性呼吸器症候群コロナウイルス2(sars-cov-2)ポリペプチドおよびワクチン目的でのその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20305550 2020-05-26
EP20305550.4 2020-05-26
EP20306415.9 2020-11-20
EP20306415 2020-11-20
EP21305092.5 2021-01-26
EP21305092 2021-01-26
EP21305482 2021-04-12
EP21305482.8 2021-04-12
PCT/EP2021/064098 WO2021239838A2 (en) 2020-05-26 2021-05-26 Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025279763A Division JP2026062799A (ja) 2020-05-26 2025-12-24 重症急性呼吸器症候群コロナウイルス2(sars-cov-2)ポリペプチドおよびワクチン目的でのその使用

Publications (3)

Publication Number Publication Date
JP2023528017A JP2023528017A (ja) 2023-07-03
JP2023528017A5 true JP2023528017A5 (cg-RX-API-DMAC7.html) 2024-06-17
JP7858550B2 JP7858550B2 (ja) 2026-05-14

Family

ID=76159441

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022573138A Active JP7858550B2 (ja) 2020-05-26 2021-05-26 重症急性呼吸器症候群コロナウイルス2(sars-cov-2)ポリペプチドおよびワクチン目的でのその使用
JP2025279763A Withdrawn JP2026062799A (ja) 2020-05-26 2025-12-24 重症急性呼吸器症候群コロナウイルス2(sars-cov-2)ポリペプチドおよびワクチン目的でのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025279763A Withdrawn JP2026062799A (ja) 2020-05-26 2025-12-24 重症急性呼吸器症候群コロナウイルス2(sars-cov-2)ポリペプチドおよびワクチン目的でのその使用

Country Status (9)

Country Link
US (1) US20230212231A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157343A2 (cg-RX-API-DMAC7.html)
JP (2) JP7858550B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230042222A (cg-RX-API-DMAC7.html)
BR (1) BR112022024063A2 (cg-RX-API-DMAC7.html)
CA (1) CA3184802A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022018389A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022014943A (cg-RX-API-DMAC7.html)
WO (1) WO2021239838A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108373509A (zh) * 2009-03-10 2018-08-07 贝勒研究院 靶向抗原呈递细胞的抗病毒疫苗
WO2022043551A2 (en) * 2020-08-31 2022-03-03 Curevac Ag Multivalent nucleic acid based coronavirus vaccines
JP2024540505A (ja) * 2021-11-17 2024-10-31 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル ユニバーサルサルベコウイルスワクチン
CN114807179B (zh) * 2022-06-01 2022-10-21 广州达博生物制品有限公司 一种新型冠状病毒肺炎疫苗的构建与应用
WO2025023616A1 (ko) * 2023-07-21 2025-01-30 세종대학교산학협력단 항 cd98 단일클론항체 및 이의 용도

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
CN100588430C (zh) * 2004-02-20 2010-02-10 复旦大学 基于表位的SARS-Cov基因疫苗及其构建
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2684889A3 (en) 2007-02-02 2014-03-05 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010009346A2 (en) 2008-07-16 2010-01-21 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
BRPI1009454A2 (pt) * 2009-03-10 2019-09-24 Baylor Res Institute vacinas contra o câncer direcionadas a células apresentadoras de antígenos
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
WO2011032161A2 (en) 2009-09-14 2011-03-17 Baylor Research Institute Vaccines directed to langerhans cells
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
KR20130108295A (ko) 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
WO2014085580A1 (en) * 2012-11-28 2014-06-05 Baylor Research Institute Methods and compositions involving a flu vaccine
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
TR201811077T4 (tr) 2013-09-06 2018-08-27 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
US10849972B2 (en) * 2018-11-27 2020-12-01 King Adulaziz University Trimeric S1-CD40L fusion protein vaccine against Middle East respiratory syndrome-coronavirus
IT202000009625A1 (it) * 2020-04-30 2021-10-30 Takis S R L Polinucleotidi codificanti antigeni di sars-cov-2 e relativo uso in campo medico come vaccini.

Similar Documents

Publication Publication Date Title
US20230303718A1 (en) Modified Antibody
US20210221904A1 (en) Fusion proteins comprising an anti-cd40 antibody and hiv antigenic peptides
CA2754743C (en) Antigen presenting cell targeted anti-viral vaccines
JP5363432B2 (ja) 樹状細胞−t細胞の相互作用を調節するための組成物及び方法
EP2406286B1 (en) Anti-cd40 antibodies and uses thereof
Borrebaeck Strategy for the production of human monoclonal antibodies using in vitro activated B cells
TWI423985B (zh) 利用dectin-1活化人類抗原呈現細胞之醫療應用
TW200902061A (en) Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
KR20130036246A (ko) 사람 cd8+ t 세포의 수지상 세포 면역수용체(dcir)-매개 교차프라이밍
JP2010518024A (ja) 樹状細胞アシアロ糖タンパク質受容体(dc−asgpr)を介して抗原提示細胞に結合する作用物質
KR20090127886A (ko) 수지상 세포 렉틴 유사 산화된 ldl 수용체-1(lox-1)을 통한 사람 항원제시세포의 활성화
JP2023554587A5 (cg-RX-API-DMAC7.html)
WO1998033523A1 (en) Vaccination methods and molecules
AU2012245170A1 (en) Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr)
CN103044552A (zh) 人源化的抗树突状细胞表面dec-205分子的单克隆抗体
HK1153501A (en) Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr)
Lee et al. Expression of a Functional Single-Chain
HK1227905A1 (en) Antigen presenting cell targeted vaccines
HK1227905A (en) Antigen presenting cell targeted vaccines
HK1178546A (en) Antigen presenting cell targeted vaccines
HK1191026A (en) Antigen presenting cell targeted cancer vaccines